News articles about Mirna Therapeutics (NASDAQ:MIRN) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mirna Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.0853012151435 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Mirna Therapeutics (MIRN) traded up 0.60% during mid-day trading on Friday, hitting $1.68. The stock had a trading volume of 4,971 shares. The stock has a 50 day moving average of $1.62 and a 200-day moving average of $1.93. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.42. The stock’s market capitalization is $35.04 million.

Separately, Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price objective on shares of Mirna Therapeutics in a report on Thursday, April 13th. Six investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and a consensus target price of $3.63.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/07/28/mirna-therapeutics-mirn-getting-somewhat-positive-media-coverage-report-shows.html.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

Insider Buying and Selling by Quarter for Mirna Therapeutics (NASDAQ:MIRN)

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.